FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...

FDA approves Novartis’ Itvisma, first gene therapy for SMA patients 2 and older

Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...
The American Journal of Managed Care

FDA Approves Gene Therapy Onasemnogene Abeparvovec for Broader SMA Population

Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...
Managed Healthcare Executive

FDA approves $2.59 million gene therapy for SMA

The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...
Pharmaceutical Technology on MSN

Novartis secures approval from FDA for Itvisma to treat SMA

The approval is supported by findings from the open-label Phase IIIb STRENGTH study and the Phase III STEER study.
Zacks Investment Research on MSN

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

Novartis NVS obtained FDA approval for onasemnogene abeparvovec-brve, a gene replacement therapy, for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The therapy ...
SMA News Today

FDA approves SMA gene therapy Itvisma for patients 2 and older

The U.S. Food and Drug Administration has approved Itvisma as the first gene therapy for spinal muscular atrophy patients ...
gadgets360

Luminous Inverters Price List

Looking to buy an Luminous inverter? Here’s a database of the latest models from the company, along with useful filters and sorting tools to let you find the most suitable one for you. With the help ...